GeoVax $3.6 Million Award Increased by U.S. Government. Cytomedix Submits 510(k) to FDA for Bone Marrow Indication Print E-mail
By Staff and Wire Reports   
Thursday, 01 September 2011 19:39
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 01, 2011.

GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced the increase of an existing $3.6 million annual award to $4.4 million for its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax’s HIV/AIDS vaccine program.

This five-year grant was originally awarded in 2007 to GeoVax by the National Institutes of Health-National Institute of Allergy & Infectious Disease (NIH-NIAID), an agency of the U.S. government. The increase reflects an administrative supplement to support vaccine response characterization. Only highly successful IPCAVD grants receive supplements, which allow these successful programs to move more rapidly. This most recent supplement for the 2011-12 grant year is the third for the GeoVax program, bringing the initial award of $15.4 million now to an aggregate award of $20.4 million.

Harriet Robinson, Ph.D., GeoVax’s Chief Scientific Officer, stated, “This award is important for the advancement of our GM-CSF adjuvanted vaccine that is achieving unprecedented levels of prevention of infection. When we started this project, I thought we could only control, not prevent, infections. It is truly wonderful to be achieving high levels of prevention of infection, and we are working very hard to move the vaccine through the needed efficacy trials for human use.”

---

Cytomedix, Inc.  (OTC:CMXI), announced the recent submission of a 510(k) to the U.S. Food and Drug Administration ("FDA") for use of the Angel Whole Blood Separation System for processing a bone marrow aspirate. The expanded indication includes processing a mixture of blood and bone marrow, a rich source of stem cells.



Also Thursday:



Adolor Corporation (NasdaqGM: ADLR) today announced that Michael R. Dougherty, President and Chief Executive Officer, will present at the William Blair & Company 2011 Life Sciences Conference on Wednesday, September 7, 2011, at 2:00 P.M. Eastern Daylight Time.

AeroGrow International, Inc. (PINKSHEETS: AERO) ("AeroGrow" or the "Company"), makers of the AeroGarden® line of indoor gardening products, announced results for the quarter ended June 30, 2011.

American CryoStem Corporation (OTCBB: CRYO) announced the grant to it of a patent by the United States Patent Office (USPTO).

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at the Stifel Nicolaus 2011 Healthcare Conference at 3:50 p.m. ET on Thursday, September 8, 2011 in Boston, Massachusetts.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Stifel Nicolaus 2011 Healthcare Conference on Thursday, September 8, 2011 at 10:55 a.m. ET at the Four Seasons in Boston.

ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the Stifel Nicolaus 2011 Global Healthcare Conference on Thursday, September 8, 2011 at 9:45 a.m.

BioDrain Medical, Inc. (OTCBB: BIOR) (OTCQB: BIOR), producer of the FDA cleared Streamway® System for automated surgical fluid disposal, today announced the company will hold a conference call on Thursday, September 8, 2011 at 11 a.m. Eastern time.

Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM)
("Biostar" or "the Company"), a Xianyang-based manufacturer of a leading PRC over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules and a variety of pharmaceutical products, today announced that the management team of Biostar, including Mr. Wang Ronghua, Chief Executive Officer and Chairman of the Board of Directors, Ms. Ally Gong, Secretary to the Board and Mr. Zack Pan, Chief Financial Officer, will attend Rodman & Renshaw Annual Global Investment Conference on September 11-13, 2011 at The Waldorf=Astoria, New York, United States of America.

Bristol-Myers Squibb Company (NYSE:BMY) today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation (ESOT) Congress on September 4 -7, 2011 in Glasgow, Scotland, United Kingdom.

Cardium Therapeutics (NYSE Amex: CXM) today announced that Christopher J. Reinhard, Chairman and Chief Executive Officer, will present at the Rodman & Renshaw Annual Healthcare Investment Conference on Tuesday, September 13, 2011, at 2:25 p.m. Eastern Time.

Catalyst Health Solutions, Inc. (NASDAQ: CHSI) announced today that David Blair, Chief Executive Officer, is scheduled to present at the William Blair 5th Annual Emerging Growth Stock Conference on Thursday, September 8, 2011, at approximately 12:30 p.m. (ET) in New York.

China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that the Company's wholly-owned subsidiary Renhuang Pharmaceutial Limited has established a key research laboratory ("the laboratory") in cooperation with Key Laboratory of Forest Plant Ecology (KLP), which is sponsored by Ministry of Education and supported by Northeastern Forest University.

CNS Response, Inc. (OTCBB: CNSO) today announced that CEO George Carpenter will be presenting at the Rodman & Renshaw 13th Annual Healthcare Conference to be held on September 11 - 13, 2011, at the Waldorf Astoria Hotel in New York, NY.

CytoSorbents Corporation (OTCBB: CTSO), a critical care-focused company using blood purification to treat life-threatening illnesses, announced it will exhibit at the 5th International Congress of the German Sepsis Society from September 7-10, 2011 in Booth #14 at the Weimarhalle Congress Center in Weimar, Germany.

Delcath Systems, Inc. (NASDAQ: DCTH)
reported top-line results from the metastatic colorectal (adenocarcinoma) cohort of the Phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancer.

diaDexus, Inc. (OTC Bulletin Board: DDXS.OB), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today said that it plans to present at Baird's 2011 Health Care Conference on Thursday, September 8, 2011 at 9:30 am Eastern Time (6:30 am Pacific Time) at the New York Palace Hotel in New York City, NY.

Esterline Corporation (NYSE: ESL) (www.esterline.com), a leading specialty manufacturer serving aerospace/defense markets, today reported its fiscal 2011 third quarter (ended July 29) income from continuing operations of $37.7 million, or $1.21 per diluted share, on sales of $409.5 million.

Fero Industries, Inc. (OTCQB: FROI) (the "Company") is pleased to announce the appointment of Luis Manuel Ornelas Lopez to the position of President.

GeoVax Labs, Inc.(OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced the increase of an existing $3.6 million annual award to $4.4 million for its Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS vaccine program.

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at two upcoming financial conferences, the William Blair Life Sciences Conference in New York and the Stifel Nicolaus Healthcare Conference in Boston.

Heska Corporation (NASDAQ: HSKA), a leading provider of veterinary diagnostic and specialty products, announces the beginning of the 2nd Annual Inspiration in Action Contest at the Central Veterinary Conference in Kansas City, MO (http://www.thecvc.com/cvc/cathome/catHome3.jsp ).

Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Stifel Nicolaus' Healthcare Conference 2011 on Thursday, September 08, 2011 at 2:05 p.m. ET at the Four Seasons Hotel in Boston.

Lannett Company, Inc. (NYSE Amex: LCI), a manufacturer of generic pharmaceuticals, today announced that the company will release its fiscal 2011 fourth-quarter and full-year financial results on Wednesday, September 7, 2011.

McKesson Corporation (NYSE:MCK) today announced that Jeff Campbell, executive vice president and chief financial officer, will present at the following conferences.

NeoGenomics, Inc. (NASD OTCBB: NGNM) announced today that it will present at the Rodman & Renshaw Annual Healthcare Investment Conference being held from September 11-13, 2011 at the Waldorf Astoria Hotel in New York City.

Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that Dr. Mark Pykett, Neoprobe’s President and Chief Executive Officer, will deliver a presentation to institutional investors at 10:20 AM ET, Thursday, September 8, 2011 at the Stifel Nicolaus Healthcare Conference 2011, taking place at The Four Seasons Hotel, Boston.

Neuralstem, Inc. (NYSE Amex: CUR) announced that President and CEO Richard Garr will present at the 2011 Stifel Nicolaus Annual Healthcare Conference on Wednesday, September 7 at 8:00 a.m. EDT.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Stifel Nicolaus 2011 Healthcare Conference in Boston.

NeuroMetrix, Inc. (Nasdaq: NURO), a science-based health care company improving patient care through neurotechnology, today announced the effectiveness of a one-for-six reverse stock split of its common stock.

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that senior management will present at the following investor conferences.

Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on August 31, 2011 the Compensation Committee of its Board of Directors approved the grant of inducement stock options to purchase an aggregate of 113,750 shares of common stock to 14 new employees.

Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:50 pm ET on Thursday, September 8, 2011 at the Stifel Nicolaus 2011 Healthcare Conference which will be held in Boston.

Sectra (NASDAQ OMX) has completed a mammography-modality deal with Royal Philips Electronics (AEX: PHI, NYSE: PHG).

Solazyme, Inc. (NASDAQ: SZYM), a renewable oil and bioproducts company, announced today it has been selected by the World Economic Forum as a 2012 Technology Pioneer.

Spectrum Pharmaceuticals (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, announced today that an overview of the Company’s business strategy will be given at the Stifel Nicolaus 2011 Healthcare Conference, being held at the Four Seasons Hotel in Boston, Massachusetts.

Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced James Levine, President and Chief Executive Officer, will present at two upcoming conferences.

Versus Technology, Inc. (PINKSHEETS: VSTI) ("Versus" or the "Company") announced revenues of $1,520,000 for its third fiscal quarter ended July 31, 2011, a 15.4% decrease compared to revenues of $1,797,000 for the same quarter of the prior year.

VIVUS,Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug application (NDA) for its investigational drug candidate, avanafil, for the treatment of erectile dysfunction (ED).

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 2011 Bank of America Merrill Lynch Global Healthcare Conference on Thursday, September 15, 2011 at 8:55 am BST (3:55 am EDT) at Merrill Lynch Financial Center, London.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter